Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more If you want to breeze through airports, train stations, and city streets hands-free, a great travel ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Elissa Sanci Elissa Sanci is a senior writer who has reported on label makers, ...